111 related articles for article (PubMed ID: 7944418)
1. [Pharmacokinetic studies on continuous intraportal 5-fluorouracil infusion].
Matsuzaki H; Yamamura T; Hanai A; Oikawa H; Kikuchi K; Seo K; Ozasa T; Akaishi O; Tsukikawa S; Yamaguchi S
Gan To Kagaku Ryoho; 1994 Sep; 21(13):2121-3. PubMed ID: 7944418
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetic studies of continuous and bolus intraportal 5-fluorouracil infusion].
Hanai A; Yamamura T; Matsuzaki H; Oikawa H; Kikuchi K; Ozasa T; Akaishi O; Senda T; Katayama K
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1536-9. PubMed ID: 1530302
[TBL] [Abstract][Full Text] [Related]
3. [Distribution of 5-FU in rat plasma and liver tissue after local 5-FU infusion].
Zheng JL; Liang LJ; Hu WJ; Shen SL
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):823-7. PubMed ID: 18504211
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer].
Lin AD; Sun HY; Qu MW; Wang FJ; Wang JY; Li ZJ
Ai Zheng; 2002 Apr; 21(4):424-9. PubMed ID: 12452026
[TBL] [Abstract][Full Text] [Related]
5. [An experimental study on portal infusion of 5-fluorouracil (the second report)].
Ishida H; Iwama T; Ide A; Nihei Z; Imajo M; Mishima Y
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1532-5. PubMed ID: 1530301
[TBL] [Abstract][Full Text] [Related]
6. [In vivo comparative study of the pharmacokinetics of chemotherapeutic agents infused via hepatic artery or portal vein against hepatic metastases. DRC Group].
Naomoto Y; Gochi A; Hizuta A; Iwagaki H; Matsuno T; Hamazaki K; Tanaka N; Orita K
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1555-8. PubMed ID: 8373217
[TBL] [Abstract][Full Text] [Related]
7. Tissue levels of chemotherapeutic agents for hepatic metastasis during hepatic arterial and portal injection.
Kaneko A; Naomoto Y; Aoyama M; Tanaka N
In Vivo; 1999; 13(2):195-8. PubMed ID: 10363178
[TBL] [Abstract][Full Text] [Related]
8. [Superior mesenteric arterial infusion chemotherapy in patient with both peritoneal carcinomatosis and liver metastasis].
Ueshima Y; Taniguchi H; Miyata K; Suganuma Y; Takeuchi K; Oguro A; Tsukuda N; Takahashi T
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1731-3. PubMed ID: 1530343
[TBL] [Abstract][Full Text] [Related]
9. [An experimental study on portal infusion of 5-fluorouracil].
Ishida H; Iwama T; Nishioka Y; Endo S; Okubo Y; Imajo M; Otomo M; Mishima Y
Gan To Kagaku Ryoho; 1991 Aug; 18(11):1884-8. PubMed ID: 1877831
[TBL] [Abstract][Full Text] [Related]
10. [Experimental study on adequate 5-FU dose and flow volume for continuous arterial liver infusion].
Mori T; Iwasaki Y; Takahashi K; Takahashi T
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1547-9. PubMed ID: 1530305
[TBL] [Abstract][Full Text] [Related]
11. Studies on the first-pass metabolism of ebastine in rats.
Fujii T; Matsumoto S; Hatoyama T; Miyazaki H
Arzneimittelforschung; 1997 Aug; 47(8):949-53. PubMed ID: 9296281
[TBL] [Abstract][Full Text] [Related]
12. Establishment of an experimental model for continuous intraportal infusion of chemo/immunotherapeutic agents in the rat.
Rafique M; Adachi W; Shiohara E
Anticancer Res; 1995; 15(5B):1869-72. PubMed ID: 8572571
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of 5-fluorouracil concentration in peripheral blood and side effects in continuous hepatic arterial infusion chemotherapy for patients with unresectable liver cancer].
Fujii K; Nakashima K; Ohno T; Anai H
Gan To Kagaku Ryoho; 1997 Sep; 24(12):1835-7. PubMed ID: 9382545
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetic comparison of intraperitoneal and intravenous 5-Fu administration].
Qing SH
Zhonghua Zhong Liu Za Zhi; 1991 Sep; 13(5):340-2. PubMed ID: 1782844
[TBL] [Abstract][Full Text] [Related]
15. [Dose, administration time and route and hepatic function-dependent metabolism of 5-FU in mice].
Okamoto M; Takao A; Fujita H
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3483-90. PubMed ID: 3789759
[TBL] [Abstract][Full Text] [Related]
16. Superiority of hepatic arterial infusion in preventing catabolism of 5-FU compared with portal vein infusion revealed by an in vivo 19F NMR study.
Okuno K; Hirai N; Lee YS; Tarabar D; Ueno H; Yasutomi M
Cancer Chemother Pharmacol; 1998; 42(4):341-4. PubMed ID: 9744781
[TBL] [Abstract][Full Text] [Related]
17. [The effect of intraportal chemotherapy in terms of administered dose of 5-FU].
Yamamura T; Matsuzaki H; Tsukikawa S; Akaishi O; Ozasa T; Miyake H; Tanaka K; Seo K; Oikawa H; Hanai A; Kikuchi K; Yamaguchi S
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1461-3. PubMed ID: 8854780
[TBL] [Abstract][Full Text] [Related]
18. [Final results of a randomized clinical trial of adjuvant intraportal chemotherapy for colorectal cancer: Intraportal Chemotherapy for Colorectal Cancer Group].
Yamamura T; Yabe K; Oka H; Kouzuma T; Kawahara H; Wakayama T; Sugiura A; Hagiwara M; Ohdate K; Miyajima N; Maeda C; Okamura R; Miyahara T; Moriyama Y; Yamaguchi S; Gunji A;
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1765-71. PubMed ID: 12402427
[TBL] [Abstract][Full Text] [Related]
19. Regional pharmacokinetics of 5-bromo-2'-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions.
Kuan HY; Smith DE; Ensmiger WD; Knol JA; DeRemer SJ; Yang Z; Stetson PL
Cancer Res; 1996 Oct; 56(20):4724-7. PubMed ID: 8840990
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
